Track topics on Twitter Track topics that are important to you
While T-cell therapies can work in some patients, the use of these cells to treat cancer and viral diseases is often limited by the poor survival and proliferation of these cells in vivo. Cancer clinical trials have demonstrated that the transferred lymphocytes can recognize tumors in vitro, but human subjects often do not respond to infusion. Gene marking studies have demonstrated that the transferred cells often survive for only short periods of time in vivo, thus limiting their effectiveness.
The current invention relates to a method of using genetic modification to generate leukocytes with multiple specificities. To improve proliferation and activation of the transduced T cells, cell transfer is combined with stimulation using a second antigen. Thus, T cells are stimulated through their native T cell receptor, using a powerful immunogen, which facilitates expansion and activation. In experiments, mice receiving alloantigen stimulated cells rejected tumors while mice receiving the unstimulated cells did not reject the tumor cells. This technology represents a potential therapy for a wide variety of malignancies, and because of the genetic modification used, this therapy will be applicable to patients of any MHC type.
Researchers at the NCI seek licensing and/or co-development research collaborations for genetically modified leukocytes with multiple specificities.
Original Article: Activated Dual Specificity Lymphocytes and Their Methods of UseNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...